Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Sarclisa is a CD38 monoclonal antibody that targets the CD38 receptor on MM cells, inducing apoptosis and immunomodulatory activity. In December 2023, Sanofi reported that its Phase III IMROZ ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

The result is increased apoptosis through sustained DR engagement ... ONK’s subsequent NK-cell therapy, ONKT102, has a CD38 CAR with optimised affinity and a DR5 TRAIL variant.

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...